{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
penicillin v
to a specific field?
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
US Previously Marketed
Source:
MIVACRON by ABBVIE
(1992)
Source URL:
First approved in 1992
Source:
MIVACRON by ABBVIE
Source URL:
Class:
MIXTURE
Conditions:
Mivacurium chloride (Mivacron) is a new benzylisoquinolinium choline-like diester neuromuscular blocking drug with an onset of action at equipotent doses that is comparable to atracurium and vecuronium but slower than succinylcholine. MIVACRON (a mixture of three stereoisomers) binds competitively to cholinergic receptors on the
motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular
transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine. MIVACRON is a short-acting neuromuscular blocking agent indicated for inpatients and outpatients,
as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle
relaxation during surgery or mechanical ventilation.
Status:
Possibly Marketed Outside US
Source:
M006
(2021)
Source URL:
First approved in 2021
Source:
M006
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT03355846: Phase 4 Interventional Completed Acute Anal Fissure
(2018)
Source URL:
First approved in 2016
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Escin, a natural mixture of triterpenoid saponins isolated from horse chestnut (Aesculus hippocastanum) seeds, is used and studied as a vasoprotective anti-inflammatory, anti-edematous and anti-nociceptive agent. In traditional Chinese medicine, Escin is widely used for the treatment of cerebral edema, and chronic venous insufficiency, among other conditions while recent studies showed Escin might have antitumor effects as well. Escin reduced cell proliferation and induces apoptosis on glioma and lung adenocarcinoma cell lines. Escin suppressed the metastasis of triple‐negative breast cancer cells through inhibiting epithelial–mesenchymal transition. Furthermore, the study also showed Escin can reverse multidrug resistance through inhibition of the GSK3β/β–catenin pathway in cholangiocarcinoma cells. Escin has been proved to be well tolerated and efficiency on improving the gastrointestinal motility in patients with colorectal cancer.
Status:
Possibly Marketed Outside US
First approved in 2009
Source:
Bambermycin Concentrate by Biovet Joint Stock Company
Source URL:
Class:
MIXTURE
Targets:
Conditions:
Bambermycins (flavomycin) is a complex of antibiotics obtained from Streptomyces bambergiensis and Streptomyces ghanaensis used as a food additive for poultry and swine. Inhibitor of the in vitro transglycosylase activities of PBPs. Bambermycins complex consists mainly of moenomycins A and C. Moenomycin A is the prototype for compounds that bind to bacterial peptidoglycan glycosyltransferases (PGTs) and inhibit cell wall biosynthesis